Association of semaglutide with risk of suicidal ideation in a real-world cohort
Authors' conclusion
Our findings do not support higher risks of suicidal ideation with semaglutide compared with non-GLP1R agonist anti-obesity or anti-diabetes medications.
Study context
- Population
- Patients with overweight or obesity prescribed semaglutide or non-GLP1R agonist anti-obesity medications (mean age 50.1 years, 72.6% female); replication in patients with T2D (mean age 57.5 years, 49.2% female)overweight/obesity cohort
- Participants
- 240,618 patients
- Exposure
- Semaglutide vs non-GLP1R agonist anti-obesity or anti-diabetes medications
- Outcome
- Incident and recurrent suicidal ideation
- Follow-up
- 6-month follow-up
Methodological detailspropensity score-matched, electronic health records (TriNetX Analytics Network)
- Propensity score-matched
- Electronic health records (TriNetX Analytics Network)
Main finding
As reported in the abstract
Semaglutide vs Non-GLP1R agonistHazard ratio (95% CI)
Recurrent suicidal ideation
0.44(0.32–0.60)
- Incident suicidal ideation; CI not legibly printed
- HR 0.27
Observational data: associations, not effects.
Further findings
Suicidal ideation by sex, age and ethnicity
- Lower risk consistent across sex, age and ethnicity stratification
Suicidal ideation, T2D cohort (replication)
- T2D cohort size
- 1,589,855 patients
- Similar findings replicated in patients with T2D
Original publication
Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med. Published 5 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →